Oxidative stress in Schizophrenia: Pathogenetic and therapeutic implications

Antioxidants and Redox Signaling

Volumn 15, Issue 7, 2011, Pages 1999-2002

  Yao, Jeffrey K ^a,b,c   Reddy, Ravinder ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; FREE RADICAL; NEUROLEPTIC AGENT;

ANTIOXIDANT ACTIVITY; GENE MAPPING; HUMAN; LIPID PEROXIDATION; METABOLIC SYNDROME X; METABOLOMICS; NEUROIMAGING; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TARDIVE DYSKINESIA;

CATALASE; GLUTATHIONE PEROXIDASE; HUMANS; LIPID METABOLISM; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SCHIZOPHRENIA; SUPEROXIDE DISMUTASE;

EID: 79956014618     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2010.3646     Document Type: Review

References (33)

1. Bannister WH. From haemocuprein to copper-zinc superoxide dismutase: a history on the fiftieth anniversary of the discovery of haemocuprein and the twentieth anniversary of the discovery of superoxide dismutase. Free Radic Res Commun 5: 35-42, 1988.
2. Ben-Shachar D. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. J Neural Transm 116: 1383-1396, 2009.
3. Ben-Shachar D and Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol 59: 273-296, 2004. (Pubitemid 39752419)
4. Boekema EJ and Braun HP. Supramolecular structure of the mitochondrial oxidative phosphorylation system. J Biol Chem 282: 1-4, 2007. (Pubitemid 47076588)
5. Buckman TD, Kling A, Sutphin MS, Steinberg A, and Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res 31: 1-14, 1990. (Pubitemid 20049539)
6. Cadet JL and Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci 570: 176-185, 1989. (Pubitemid 20103394)
7. Cheng TM, Lu YE, Guest PC, Rahmoune H, Harris LW, Wang L, Ma D, Stelzhammer V, Umrania Y, Wayland MT, Lió P, and Bahn S. Identification of targeted analyte clusters for studies of schizophrenia. Mol Cell Proteomics 9: 510-522, 2010.
8. Chowdari KV, Bamne MN, and Nimgaonkar VL. Genetic association studies of antioxidant pathway genes and schizophrenia. Antioxid Redox Signal 15: 2037-2045, 2011.
9. Do KQ, Cabungcal JH, Frank A, Steullet P, and Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 19: 220-230, 2009.
10. Fucetola R, Newcomer JW, Craft S, and Melson AK. Ageand dose-dependent glucose-induced increases in memory and attention in schizophrenia. Psychiatry Res 88: 1-13, 1999. (Pubitemid 29494963)
11. Gysin R, Kraftsik R, Boulat O, Bovet P, Conus P, Comte-Krieger E, Polari A, Steullet P, Preisig M, Teichmann T, Cuénod M, and Do KQ. Genetic dysregulation of glutathione predicts alteration of plasma thiol redox status in schizophrenia. Antioxid Redox Signal 15: 2003-2010, 2011.
12. Hoffer A, Osmond H, and Smythies J. Schizophrenia: a new approach. J Ment Sci 100: 29-45, 1954.
13. Jablensky AV and Kalaydjieva LV. Genetic epidemiology of schizophrenia: phenotypes, risk factors, and reproductive behavior. Am J Psychiatry 160: 425-429, 2003.
14. Lieberman JA and Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia, a selective review. Schizophr Bull 19: 371-429, 1993. (Pubitemid 23183154)
15. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, Garvik BM, and Yates JR 3rd. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 17: 676-682, 1999. (Pubitemid 29316146)
16. Martins-de-Souza D, Harris LW, Guest PC, and Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal 15: 2067-2079, 2011.
17. Matsuzawa D and Hashimoto K. Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal 15: 2057-2065, 2011.
18. McGue M, Gottesman II, and Rao DC. The transmission of schizophrenia under a multifactorial threshold model. Am J Hum Genet 35: 1161-1178, 1983. (Pubitemid 14201169)
19. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, and Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9: 684-697, 643, 2004. (Pubitemid 38932173)
20. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, and Bahn S. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 6: 141-149, 2007. (Pubitemid 46173666)
21. Prilipko LL and Lideman RR. Lipid peroxidation processes as one of the factors modifying neuronal membrane-bound proteins in schizophrenia. Vestn Akad Med Nauk SSSR 1: 33-37, 1982.
22. Reddy R and Reddy R. Antioxidant therapeutics for schizophrenia. Antioxid Redox Signal 15: 2047-2055, 2011.
23. Reddy R, Sahebarao MP, Mukherjee S, and Murthy JN. Enzymes of the antioxidant system in chronic schizophrenic patients. Biol Psychiatry 30: 409-412, 1991.
24. Saha S, Chant D, Welham J, and McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2: e141, 2005.
25. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, McKenna P, and Bahn S. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 7: 4266-4277, 2008.
26. Shirts BH and Nimgaonkar V. The genes for schizophrenia: finally a breakthrough? Curr Psychiatry Rep 6: 303-312, 2004. (Pubitemid 39173547)
27. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, and Carpenter WT. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49: 522-530, 1992.
28. van Os J and Kapur S. Schizophrenia. Lancet 374: 635-645, 2009.
29. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Yan JX, Gooley AA, Wilkins MR, Duncan MW, Harris R, Williams KL, and Humphery-Smith I. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 7: 1090-1994, 1995.
30. Yao JK, Dougherty GG Jr., Reddy RD, Keshavan MS, Montrose DM, Matson WR, McEvoy J, and Kaddurah-Daouk R. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. PLoS One 5: e9508, 2010.
31. Yao JK and Keshavan MS. Antioxidants, redox signaling, and pathophysiology of schizophrenia: an integrative view. Antioxid Redox Signal 15: 2011-2035, 2011.
32. Yao JK, Leonard S, and Reddy RD. Increased nitric oxide radicals in postmortem brains from schizophrenic patients. Schizophr Bull 30: 923-934, 2004. (Pubitemid 40469526)
33. Yao JK, Reddy RD, and van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15: 287-310, 2001. (Pubitemid 32337052)